Analysis the prognostic values of solute carrier (SLC) family 39 genes in gastric cancer - PubMed (original) (raw)

. 2019 Jan 15;11(1):486-498.

eCollection 2019.

Affiliations

Analysis the prognostic values of solute carrier (SLC) family 39 genes in gastric cancer

Bisha Ding et al. Am J Transl Res. 2019.

Abstract

Background: Gastric cancer (GC) is one of the most common diagnosed cancer with poor prognosis. Solute carrier (SLC) family 39 genes encode membrane transport proteins, which control the influx of zinc and may play important roles in human disease including cancer. However, the prognostic value of individual SLC family 39 gene in gastric cancer patients remain unclear.

Methods: Genetic alteration frequency and mRNA expression level of SLC family 39 genes in GC were first assessed by using many online databases including cBioportal for Cancer Genomics, Oncomine, UCSC Xena browser and Ualcan database. The prognostic value of individual SLC family 39 gene in GC patients were further investigated via Kaplan-Meier plotter.

Results: The analytic results of genetic alteration frequency showed that mRNA deregulation was one of the most important single factors for alteration in different kinds of gastric cancer. Compared with normal gastric tissues, 14 SLC family 39 genes were all significantly upregulated in GC tissue in Ualcan database, and SLC39A4, SLC39A5, SLC39A6, SLC39A10 mRNA expression were also higher in Oncomine database. The survival analysis indicated that most members of SLC family 39 genes were closely related with prognosis of GC patients, SLC39A7, SLC39A11, SLC39A14 were significantly associated with favorable overall survival (OS), the rest of SLC family 39 genes were importantly correlated with unfavorable OS except SLC39A10.

Conclusion: Our analysis identified that 14 SLC family 39 genes are potential prognostic biomarkers of GC patients, and may offer effective and new strategies for GC therapy.

Keywords: Solute carrier (SLC) family 39 genes; gastric cancer; prognosis.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1

Figure 1

Alteration frequency and mRNA expression of SLC family 39 in GC. A. Alteration frequency analysis of SLC family 39 genes in GC. The analysis was performed using uBioPortal database. (1-6 means different types of gastric cancer, 1-Papillary Stomach Adencarcinoma, 2-Tubular Stomach Adencarcinoma, 3-Mucinous Stomach Adencarcinoma, 4-Stomach carcinoma, 5-Diffuse Type Stomach Adencarcinoma, 6-Signet Ring Cell Carcinoma of the Stomach). B. Partly mRNA expression of SLC family 39 genes (SLC39A4, SLC39A5, SLC39A6, SLC39A10) differences between cancer and normal tissues in GC using Oncomine, others are not measured. C. 14 SLC family 39 genes expression differences in GC using UCSC Xena browser.

Figure 2

Figure 2

mRNA expression of SLC family 39 genes varied in primary tumor and in corresponding normal tissues in GC patients using Uaclan database. A-N. All solute carrier family 39 genes show high expression in gastric tumor tissues compared with gastric normal tissues.

Figure 3

Figure 3

OS analysis of SLC family 39 genes in GC patients using Kaplan-Meier plotter.

Figure 4

Figure 4

The correlation between GC patients OS, FP (First Progression), PPS (Post Progression Survival) and SLC family 39 genes expression.

Similar articles

Cited by

References

    1. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014;23:700–13. - PMC - PubMed
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. - PubMed
    1. Van Cutsem E, Sagaert X, Topal B, Haustermans K, Prenen H. Gastric cancer. Lancet. 2016;388:2654–2664. - PubMed
    1. You X, Ma M, Hou G, Hu Y, Shi X. Gene expression and prognosis of NOX family members in gastric cancer. Onco Targets Ther. 2018;11:3065–3074. - PMC - PubMed
    1. Lin L, Yee SW, Kim RB, Giacomini KM. SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. 2015;14:543–60. - PMC - PubMed

LinkOut - more resources